


Current information on most recent advances regarding CNS risk assessment and approaches to CNS prophylaxis in patients with DLBCL



Clinical risk models: International Prognostic Index (IPI) scores

5 risk factors

- 1- Age > 60 years
- 2- Elevated lactate dehydrogenase (LDH)
- 3- Eastern Cooperative Oncology Group Performance Status (ECOG-PS) > 1
- 4- Advanced stage disease
- 5- Involvement of more than one extranodal site

High-risk extranodal sites

- Testicular involvement*
 - Bone marrow
 - Paranasal sinus
 - Orbital
 - Pericardial
 - Ovarian
 - Uterine
 - Breast
 - Kidney
 - Adrenal involvement
- *CNS relapse rates: 12-25%

Biologic risk factors

- *MYC* rearrangement
- Translocations of *MYC* and *BCL2* and/or *BCL6* (**double- or triple-hit lymphoma**)*

* Median overall survival: > 2 years

CNS prophylaxis

- **Intrathecal therapy:** methotrexate
- **Systemic chemotherapy:** methotrexate, ibuprofen, lenalidomide